Prostate Cancer - Results from #140

Evolution of myeloid-mediated immunotherapy resistance in prostate cancer. December 10, 2024

Ultra-high gradient performance 3-Tesla MRI for super-fast and high-quality prostate imaging: initial experience. December 10, 2024

Talazoparib plus enzalutamide versus olaparib plus abiraterone acetate and niraparib plus abiraterone acetate for metastatic castration-resistant prostate cancer: a matching-adjusted indirect comparison. December 10, 2024

Survival Outcomes and Recurrence Patterns Following Focal High-intensity Focused Ultrasound Treatment for Localized Prostate Cancer: Insights on Patient Selection and Lessons Learned. December 10, 2024

The Added Value of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography to Magnetic Resonance Imaging for Local Staging of Prostate Cancer in Patients Undergoing Radical Prostatectomy. December 10, 2024

Spatial Transcriptomic Profiling to Characterize the Nature of Peripheral- Versus Transition-zone Prostate Cancer. December 10, 2024

Hospital Quality and Racial Differences in Outcomes After Genitourinary Cancer Surgery. December 10, 2024

Treatment-related Hypertension as a Prognostic Factor for De Novo Metastatic Hormone-sensitive Prostate Cancer: A Retrospective Real-world Evidence Study. December 9, 2024

Cancer-Control Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer With BRCA Gene or Tumor Suppressor Mutations Undergoing 177-Lutetium Prostate-Specific Membrane Antigen Radioligand Therapy. December 9, 2024

Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients: An Updated Network Meta-analysis Including ARANOTE Data. December 9, 2024

Experience of urologists, oncologists and nurse practitioners with mainstream genetic testing in metastatic prostate cancer. December 9, 2024

Novel Methods to Assess Tumor Burden and Minimal Residual Disease in Genitourinary Cancers. December 9, 2024

Recent and Future Developments in the Use of Poly (ADP-ribose) Polymerase Inhibitors for Prostate Cancer. December 9, 2024

Proportion of Gleason Score ≥8 Prostate Cancer on Biopsy and Tumor Aggressiveness in Matched Cohorts of East Asian and Non-East Asian Men. December 9, 2024

Artificial intelligence for detection of prostate cancer in biopsies during active surveillance. December 9, 2024

Blood-based tumor mutational burden impacts clinical outcomes of immune checkpoint inhibitor treated breast and prostate cancers. December 9, 2024

Immunome profiling in prostate cancer: a guide for clinicians. December 6, 2024

Post-prostatectomy Magnetic Resonance-guided Radiotherapy on a 1.5 Tesla Magnetic Resonance Integrated Linear Accelerator: Feasibility, Toxicity, and Preliminary Clinical Outcomes. December 6, 2024

Apalutamide in Metastatic Castration-sensitive Prostate Cancer: Results from the Multicenter Real-world ARON-3 Study. December 6, 2024

Biochemical response to neoadjuvant androgen deprivation therapy before radiation therapy and the risk of death in patients with unfavorable-risk prostate cancer: A secondary analysis of a randomized clinical trial. December 6, 2024

Page 8 of 1451